Torrent Pharma buying Indian API operation


India’s Torrent Pharma, which has been beefing up its international focused production capabilities, is buying an API operation from another Indian player.

The Ahmedabad-based drugmaker today reported to the Bombay Stock Exchange that it has a binding agreement to buy the Vizag-based API manufacturing unit of Glochem Industries. It didn't give a purchase price but said the multi-product facility is approved by the FDA and EU authorities and has units for both intermediate and API production.  It also has development and quality control operations and a pilot plant.

Torrent already has four formulation plants in India and with this deal, will now have three API operations, it said in a release. "Acquisition of this site will further help in backward integration and scale up of Torrent's manufacturing capacity to meet the growing demand from international markets,” Jinesh Shah, executive director of operations at Torrent said in a statement.   


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Torrent has been on an expansion streak in the last several years, acquiring India's Elder Pharmaceuticals for $321.7 million in 2013, getting 30 Indian brands in the process. Last year it acquired Indian skin med specialist Zyg Pharma. It recently was reported to be in the mix to buy Indian sterile injectables maker Gland Pharma but sources later put Baxter ($BAX) in the front on that deal.

- access the announcement here

Related Articles:
India's Torrent Pharma targets production from new plant at U.S.
Baxter, Torrent bidding for India’s Gland Pharma: Reuters

Suggested Articles

Higher operating costs were behind a 17% slide in pretax profits last year at Allergan’s Mayo, Ireland, facility that produces Botox.

After a global scare over Zantac contamination, generic metformin could be next in line as regulators test for possible carcinogen contamination.

PCI Pharma Services debuts expansion of its plant in Rockford, Illinois.